--- title: "Weekly Recap | Roche -4.04%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/300851193.md" description: "Roche (RHHBY.US) fell 4.04% this week to close at $52.25, underperforming the S&P 500’s 0.27% decline by about 3.77 percentage points. The week was weak from the start: Monday opened at $53.35 and briefly touched $53.62 before fading, Tuesday gapped lower to $52.25, and the last three sessions traded narrowly around $52. Friday (2 Oct) closed back at $52.25. Weekly range was 3.39%, with the close sitting below both the 20-day moving average at $53.97 and the 60-day at $54.50." datetime: "2026-10-03T07:34:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300851193.md) - [en](https://longbridge.com/en/news/300851193.md) - [zh-HK](https://longbridge.com/zh-HK/news/300851193.md) generator: "portal-rs" --- # Weekly Recap | Roche -4.04%, most brokers rate it buy ## The Week Roche (RHHBY.US) fell 4.04% this week to close at $52.25, underperforming the S&P 500’s 0.27% decline by about 3.77 percentage points. The week was weak from the start: Monday opened at $53.35 and briefly touched $53.62 before fading, Tuesday gapped lower to $52.25, and the last three sessions traded narrowly around $52. Friday (2 Oct) closed back at $52.25. Weekly range was 3.39%, with the close sitting below both the 20-day moving average at $53.97 and the 60-day at $54.50. ## Key Events Company news was dense this week. Roche outlined plans to shift its labs toward autonomous AI lab operations, while Genentech broke ground on a $750 million manufacturing expansion in Hillsboro, Oregon. On the product front, the US FDA accepted fenebrutinib’s filing for multiple sclerosis under priority review, and set a 18 Dec 2026 PDUFA date for giredestrant in advanced breast cancer. Giredestrant plus everolimus also showed improved progression-free survival in ER-positive breast cancer. Vabysmo’s real-world data at EURETINA supported effectiveness across wet AMD, DME and RVO. There was a negative note as well: after Roche discontinued emugrobart, Chugai regained rights and the stock came under pressure that day. ## Analyst Ratings As of this week, 8 firms cover Roche (RHHBY.US): 2 rate it buy, 2 overweight and 4 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $60.59, about 15.95% above the latest close. The target range runs from $53.00 to $67.10, showing a fairly wide spread. Roche ranks 63rd out of 203 names in its industry group. ## The Week Ahead On the macro side, Monday (5 Oct) brings the US S&P Global services PMI final print and ISM non-manufacturing PMI, followed by trade balance data on Tuesday and EIA crude inventories on Wednesday. On the company side, Roche’s Q3 FY2026 results are due before the open on 22 Oct, with consensus revenue around $18.9 billion. FDA review timelines for fenebrutinib and giredestrant are likely to stay in focus heading into the print. ## In Short Roche shares lagged the market this week even as the company kept rolling out pipeline updates: fenebrutinib won priority review, giredestrant data improved, and Vabysmo’s real-world evidence expanded, while the emugrobart discontinuation pulled in the other direction. The analyst consensus is favourable, with the consensus target above spot, yet the wide target range points to internal disagreement over valuation. The next test is whether Q3 results can back up the recent pipeline progress, and whether FDA review dates can provide a catalyst before the stock reclaims its 50-day moving average. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) ## Related News & Research - [Roche says FDA sets Dec. 18, 2026 PDUFA date for giredestrant in advanced breast cancer](https://longbridge.com/en/news/300645219.md) - [Roche Says Giredestrant- Everolimus Combo Significantly Improves PFS In ER+ Breast Cancer](https://longbridge.com/en/news/300652681.md) - [Roche says FDA accepts fenebrutinib MS filing for priority review](https://longbridge.com/en/news/300517747.md) - [Roche outlines plans to move towards autonomous AI labs](https://longbridge.com/en/news/300294737.md) - [Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion](https://longbridge.com/en/news/300929852.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**